Literature DB >> 17889171

Role of liver transplantation in the management of unresectable neuroendocrine liver metastases.

C Marín1, R Robles, J A Fernández, F S Bueno, P Ramírez, M Miras, P Parrilla.   

Abstract

UNLABELLED: The use of OLT in the management of liver metastases of any origin is highly controversial, as most patients receiving a transplant for this indication display poor results owing to early tumor spread secondary to the effects of immunosuppression. However, as they have a better biological behavior, neuroendocrine (NE) tumors may be a good indication for OLT. Our aim was to present our experience in the management of unresectable liver metastases of tumors of NE origin. PATIENTS AND METHODS: Between January 1996 and April 2006, 10 patients underwent OLT for unresectable liver metastases of a neuroendocrine origin, accounting for 1.2% of all transplants performed to date in our unit (n = 626). The most common location of the primary tumor was the pancreas in six cases: three in the pancreatic tail--one carcinoid tumor, one gastrinoma, and one nonfunctioning NE [NF-NE] tumor; and three cases in the pancreatic head--three NF-NE tumors. In the remaining four cases, including three carcinoid tumours and one NF-NE tumors, two were located in the small bowel (at the ileum and ileocecal valve) and two in the lung. The liver metastases were synchronous with the primary tumor in seven cases and metachronous in three cases.
RESULTS: The morbidity rate was 75% and the mortality rate, 10% (n = 1). The tumor recurrence rate was 33% with 1- and 3-year survival rates of 86% and 57%, respectively.

Entities:  

Mesh:

Year:  2007        PMID: 17889171     DOI: 10.1016/j.transproceed.2007.06.040

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  5 in total

1.  Liver transplantation for metastatic neuroendocrine tumors: Outcomes and prognostic variables.

Authors:  Linda S Sher; David M Levi; Julie S Wecsler; Mary Lo; Lydia M Petrovic; Susan Groshen; Lingyun Ji; Teresa Diago Uso; A Joseph Tector; Ann S Hamilton; J Wallis Marsh; Myron E Schwartz
Journal:  J Surg Oncol       Date:  2015-07-14       Impact factor: 3.454

Review 2.  Liver transplantation for metastatic neuroendocrine tumors.

Authors:  Louise Barbier; Cindy Neuzillet; Safi Dokmak; Alain Sauvanet; Philippe Ruszniewski; Jacques Belghiti
Journal:  Hepat Oncol       Date:  2014-12-11

Review 3.  Role of surgery and transplantation in the treatment of hepatic metastases from neuroendocrine tumor.

Authors:  Sayee Sundar Alagusundaramoorthy; Roberto Gedaly
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

Review 4.  Multimodal management of neuroendocrine liver metastases.

Authors:  Andrea Frilling; Georgios C Sotiropoulos; Jun Li; Oskar Kornasiewicz; Ursula Plöckinger
Journal:  HPB (Oxford)       Date:  2010-08       Impact factor: 3.647

Review 5.  Management of patients with hepatic metastases from neuroendocrine tumors.

Authors:  Ashley Kieran Clift; Andrea Frilling
Journal:  Ann Saudi Med       Date:  2014 Jul-Aug       Impact factor: 1.526

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.